Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07144137Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Role: lead

NCT07392255Phase 1Recruiting

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Role: lead

NCT05797896Active Not Recruiting

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

Role: lead

All 3 trials loaded